Loading...
Loading...
FLGT| Name | Value |
|---|---|
| Revenues | 71.7M |
| Cost of Revenue | 45.0M |
| Gross Profit | 26.8M |
| Operating Expense | 43.9M |
| Operating I/L | -17.1M |
| Other Income/Expense | -1.5M |
| Interest Income | 8.1M |
| Pretax | -18.5M |
| Income Tax Expense | -3.8M |
| Net Income/Loss | -14.6M |
Fulgent Genetics, Inc. provides COVID-19, molecular diagnostic, and genetic testing services globally. Their offerings include genetic tests for oncology, carrier screening, solid tumor profiling, rapid whole genome testing for children, newborn genetic analysis, and patient-initiated genetic testing. They also provide next generation sequencing, reverse transcription polymerase chain reaction-based tests, and antigen-based diagnostic tests for SARS-CoV-2. Additionally, the company offers flow cytometry, fluorescence in-situ hybridization, immunohistochemistry, cytogenetics, and molecular testing for hematopoietic and solid tumors. Fulgent Genetics serves insurance, hospitals, medical institutions, laboratories, governmental bodies, payors, municipalities, large corporations, and patients.
